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Abstract All published evidence on procalcitonin (PCT)-
guided antibiotic therapy was obtained in trials where
physicians knew that they were being monitored, possibly
resulting in higher adherence to the PCT algorithm. This
study investigates the effectiveness of PCT guidance in an
observational quality control survey. We monitored antibi-
otic therapy and algorithm adherence in consecutive
patients with respiratory tract infections admitted to the
Kantonsspital Aarau, Switzerland, between May 2008 and
February 2009. The results were compared to the site-
specific results of the former ProHOSP study. Overall and
more pronounced for patients with community-acquired
pneumonia, the median duration of antibiotic treatment in
this survey was shorter than the ProHOSP control patients
(6 vs. 7 days, P=0.048 and 7 vs. 9 days, P<0.001). In
72.5% of patients, antibiotics were administered according
to the prespecified PCT algorithm. No significant differ-
ences concerning adverse medical outcome could be
detected. This study mirrors the use of PCT-guided
antibiotic therapy in clinical practice, outside of trial
conditions. If algorithm adherence is reinforced, antibiotic
exposure can be markedly reduced with subsequent
reduction of antibiotic-associated side effects and antibiotic
resistance. The integration of the PCT algorithm into daily
practice requires ongoing reinforcement and involves a
learning process of the prescribing physicians.
Introduction
In the last five years, seven consecutive randomised
controlled trials (RCTs) have demonstrated the efficacy,
effectiveness, feasibility and safety of procalcitonin (PCT)-
guided antibiotic stewardship in patients with lower
respiratory tract infections (LRTI) and sepsis [1–7].
Thereby, embedded in an easy-to-use and pragmatic clinical
algorithm, the initiation or continuation of antibiotics was
more or less discouraged or encouraged, respectively, based
on circulating PCT levels (Fig. 1). To assure practicability
and safety for patients, specific ‘overruling’ criteria were
predefined, where this algorithm could be bypassed (e.g.
imminent life-threatening disease or the need for intensive
care unit [ICU] admission) [8]. Overall, PCT-guided
antibiotic stewardship reduced the initial antibiotic pre-
scription rate by 40–50% in patients with LRTI presenting
to the emergency room [5], by 72% in ambulatory patients
presenting for an outpatient visit with the general physician
[13] and total antibiotic exposure in patients with
community-acquired pneumonia (CAP) by 48% [4], mainly
by the shortening of antibiotic courses without increasing
the rate of adverse outcomes [1–7].
P. Schuetz, M. Batschwaroff and F. Dusemund are equally
contributing first authors.
P. Schuetz
Division of Internal Medicine, University Hospital Basel,
4031 Basel, Switzerland
P. Schuetz :M. Batschwaroff : F. Dusemund :W. Albrich :
U. Bürgi :M. Maurer :M. Brutsche : B. Müller (*)










Eur J Clin Microbiol Infect Dis (2010) 29:269–277
DOI 10.1007/s10096-009-0851-0
All published evidence on PCT-guided antibiotic stew-
ardship was obtained from RCTs, and data on the
effectiveness outside of controlled study conditions are
lacking. Results from RCTs may not unconditionally be
applied to general patients due to exclusion criteria or non-
enrollment, limiting generalisability. In addition, it is well
known that results obtained in RCTs are frequently not
adequately implemented in daily practice. For instance,
patients with CAP are often admitted to in-hospital care,
despite their low risk for mortality as assessed with the
pneumonia severity index (PSI) and guideline recommen-
dation to treat as outpatients [9, 10]. Non-adherence to CAP
guidelines in real life can also be observed in relation to
other decisions, e.g. the timely administration of antibiotics
or collection of blood cultures. An impressive example of
an unanticipated effect of introducing a study result was a
marked increase in the rates of hyperkalaemia observed in
the post-study population-based surveillance in patients
with congestive heart failure treated with spironolactone
according to the results of the RALES trial [11]. Of note,
the risk of hyperkalaemia was listed as rare in the original
RALES report [12].
In this context, this survey aims to investigate the
effectiveness of PCT-guided antibiotic stewardship in an
observational quality control survey to better mirror the
‘real-life’ setting and, thereby, to prevent misuse.
Methods
Subjects and study design
This quality control survey monitored the initiation and
duration of antibiotic therapy, adherence to the published
PCT algorithm (Fig. 1) and outcome of all consecutive
patients with LRTI admitted to the Kantonsspital Aarau,
Switzerland, between May 2008 and February 2009. The
same hospital participated until March 2008 as an active
recruitment site in the multicentre ProHOSP study [2, 7].
This study prospectively randomised patients to receive
antibiotic therapy based either on PCT cut-off ranges (PCT
intervention group) or based on enforced guidelines
(control group). For this survey, the diagnostic work-up,
including chest radiograph and the treatment of patients,
was left to the discretion of the treating physicians. PCT
was measured in all patients with LRTI in a clinical routine
using a highly sensitive immunoassay with a functional
assay sensitivity of 0.06µg/L (Kryptor®, BRAHMS AG,
Hennigsdorf, Germany).
For this survey, all patients with LRTI who were
admitted to the hospital were Web-based registered by the
physician on duty. Physicians were blinded to the aim of
the survey and reminded of the need for registration three-
monthly. The same PCT algorithm which was used during
the ProHOSP study (Fig. 1) was displayed in the
emergency department. New resident and attending physi-
cians were briefed about this surveillance study.
The local Institutional Review Board (Kantonale
Ethikkommission Aargau, Departement Gesundheit und
Soziales) classified this study as an observational quality
surveillance and, thus, waived the need for patient informed
consent.
Definitions
Similar to the definition used in the ProHOSP study, LRTI
was defined as the presence of at least one respiratory
symptom (cough, sputum production, dyspnoea, tachyp-
Fig. 1 Procalcitonin (PCT) algorithm
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noea, pleuritic pain) plus at least one finding during
auscultation (rales, crepitation) or one sign of infection
(core body temperature >38.0°C, shivering, leukocyte count
>10G/l or <4G/l cells) independent of antibiotic pre-
treatment. In accordance with guidelines, CAP was defined
as a new infiltrate on chest radiograph [13–16]. GOLD
criteria were used to define chronic obstructive pulmonary
disease (COPD) by post-bronchodilator spirometric criteria
as an FEV1/FVC ratio below 70% and to categorise the
severity [13, 17]. Acute bronchitis was defined as LRTI in
the absence of an underlying lung disease or focal chest
signs and infiltrates on chest radiograph, respectively [14].
Monitoring of patients
Upon admission, the following data were prospectively
recorded by a member of the study team: age, gender and
comorbidity of patients, results of prognostic and diagnostic
work-up, i.e. parameters included in the PSI [10] and
CURB65 score, blood culture and urine antigen test for
Legionella pneumophila. After discharge of the patients, the
database was completed with information about the duration
and route of antibiotic therapy, total length of hospital stay
and adverse medical outcomes, including all-cause in-
hospital mortality, ICU admission, complications (e.g. empy-
ema) and recurrence rate during the index hospitalisation.
The survey ended when patients were discharged from the
hospital and we did not perform additional follow up.
Endpoints
The primary endpoint of this study was the total duration of
antibiotic treatment. We used data from the ProHOSP study
participants of the same hospital to compare the results of
this survey. Thereby, we used the ProHOSP intervention
group as positive controls and the ProHOSP control group
as negative controls.
Secondary endpoints were adherence to the PCT
algorithm, adverse medical outcomes, all-cause mortality,
ICU admission, complications and recurrence rate within
the index hospitalisation and length of hospital stay.
Adherence with the PCT algorithm was evaluated indepen-
dently by two members of the research group (MB and PS)
after a patient was discharged. The evaluation was based on
adherence to the previously published PCT algorithm
(Fig. 1). In brief, the initiation or continuation of antibiotics
was discouraged if PCT levels were ≤0.25 μg/L and
encouraged if PCT levels were >0.25 μg/L. In addition, in
patients with very low PCT levels (<0.1 μg/L), antibiotics
were strongly discouraged, while they were strongly
encouraged in patients with PCT levels >0.5 μg/L. In case
antibiotics were withheld, clinical re-evaluation and a
repeated measurement of PCT was recommended after 6–
24 h. If PCT values were increased and antibiotic therapy
was initiated, repeated PCT measurements were recom-
mended and antibiotics were discontinued using the same
cut-off ranges. In patients with very high initial PCT values
(i.e. >5–10 μg/L), the discontinuation of antibiotic therapy
was encouraged if levels decreased by 90% or at least 80%
of the initial value. In addition, the same specific ‘over-
ruling’ criteria were defined as in the initial studies [7]
where this algorithm could be bypassed (e.g. life-
threatening disease or immediate need for ICU admission).
Accordingly, non-adherence was defined if antibiotic
therapy was initiated or not discontinued, despite low
PCT levels in the absence of any of the predefined criteria.
Statistical analysis
Discrete variables were expressed as counts (percentage) and
continuous variables as medians and interquartile ranges
(IQR), unless stated otherwise. Frequency comparison was
done by the Chi-square test. Two-group comparison of
normally distributed data was performed by Student’s t-test.
For data not normally distributed, the Mann–WhitneyU-test
was used. All statistical analyses were done by the SPSS
Statistics package (version 17.0, SPSS Inc., Chicago, IL,
USA) and STATA 9.2 (Stata Corp., College Station, TX,
USA). All testing was two-tailed and P-values less than
0.05 were considered to indicate statistical significance.
Results
Baseline characteristics
Three hundred and two patients were included in this
survey with a median age of 71 years and 68% were male.
CAP was diagnosed in 71.9%, while in 18.5% acute
bronchitis and in 9.6% acute exacerbation of COPD was
diagnosed. Table 1 shows the baseline characteristics of the
survey population as compared to patients in the control
and the intervention group of the ProHOSP study. Clinical
findings and most co-existing illnesses at presentation were
similar in all three of the compared groups. Neoplastic
disease and immunosuppression were more frequent in the
survey population. In addition, survey patients had a higher
frequency of CAP with higher severity as assessed with the
PSI. In addition, the initial serum levels of PCT, C-reactive
protein and white blood cell count were similar in the
survey population as compared to ProHOSP patients.
Primary endpoint: duration of antibiotic treatment
The overall median duration of antibiotic treatment in the
survey population of 6 days was lower than in the
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ProHOSP control group (7 days, P<0.05), and tended to be
higher compared to the ProHOSP intervention group (4 days,
P=0.08). In the subgroup of patients with CAP, the median
duration of antibiotic treatment in the survey was signifi-
cantly lower compared to the ProHOSP control group
(7 days vs. 9 days, P<0.001) and similar to the ProHOSP
intervention group (7 days vs. 7 days, P=0.24). Detailed
antibiotic courses of CAP patients in the different study
groups are presented in Fig. 2. In the subgroup of patients
with exacerbation of COPD, the overall treatment duration
was again lower in the survey as compared to the ProHOSP
control group (0 days vs. 4 days, P<0.05) and tended to be
lower as compared to the intervention group (0 days vs.
3 days, P=0.08). For patients with bronchitis, no significant
Table 1 Baseline characteristics of patients included in the survey and the ProHOSP study












Age (years) 71 (55–81) 67 (49–80) 70 (54–79) P=0.18 P=0.54
Sex (male), no. (%) 186 (68%) 72 (59.5%) 74 (63.8%) P=0.69 P=0.68
Coexisting illnesses, no. (%)
Coronary heart disease 44 (14.6%) 21 (17.4%) 20 (17.2%) P=0.47 P=0.5
Cerebrovascular disease 0 (0%) 8 (6.6%) 8 (6.9%) P<0.0001 P<0.0001
Renal dysfunction 118 (39.1%) 29 (24%) 36 (31%) P=0.003 P=0.13
COPD 112 (37.1%) 48 (39.7%) 39 (33.6%) P=0.62 P=0.51
Neoplastic disease 85 (28.1%) 14 (11.6%) 18 (15.5%) P<0.0001 P=0.007
Immunosuppression 20 (6.6%) 1 (0.8%) 2 (1.7%) P=0.01 P=0.045
Diabetes 56 (18.5%) 22 (18.2%) 19 (16.4%) P=0.93 P=0.61
Clinical findings
Confusion, no. (%) 30 (9.9%) 4 (3.3%) 6 (5.2%) P<0.0001 P<0.0001
Respiratory rate (breaths/min) 24 (20–28) 20 (16–25) 20 (16–24) P<0.0001 P<0.0001
Systolic blood pressure (mmHg) 130 (114–145) 125 (120–140) 130 (117–143) P=0.19 P=0.58
Heart rate (beats/min) 97 (80–110) 92 (80–105) 90 (79–100) P=0.09 P=0.007
Body temperature (°C) 37.9 (37–38.6) 37.9 (37.2–38.8) 38 (37.1–38.7) P=0.34 P=0.43
Laboratory findings
Procalcitonin (μg/l) 0.28 (0.12–1.08) 0.21 (0.08–0.93) 0.16 (0.08–0.62) P=0.05 P=0.001
C-reactive protein (mg/l) 90 (28–185) 87 (29–172) 75 (26–144) P=0.95 P=0.29
WBC (×109/l) 10.9 (7.5–15.2) 10.9 (8–14.5) 10.8 (8.1–14.3) P=0.85 P=0.85
Final diagnosis, no. (%)
CAP 217 (71.9%) 66 (54.5%) 71 (61.2%) P=0.001 P=0.04
Exacerbation of COPD 29 (9.6%) 25 (20.7%) 20 (17.2%) P=0.002 P=0.03
Bronchitis 56 (18.5%) 26 (21.5%) 21 (18.1%) P=0.49 P=0.92
Other final diagnosis – 4 (3.3%) 4 (3.4%) P=0.001 P=0.001
Risk assessment in CAP patients
PSI points 103 (72–129) 84 (52–106) 90 (60–113) P<0.001 P=0.004
PSI class IV or V, no. (%) 185 (61.3%) 53 (43.8%) 56 (48.3%) P=0.001 P=0.02
CURB65 1 (1–2) 1 (0–2) 1 (0–2) P=0.07 P=0.01
Data are expressed as median (interquartile range, IQR), unless stated otherwise
Fig. 2 Course of antibiotic treatment in community-acquired pneu-
monia (CAP) patients from the ProHOSP (intervention and control
group) study and survey patients
272 Eur J Clin Microbiol Infect Dis (2010) 29:269–277
difference was found between groups. Table 2 shows more
details on the primary and secondary endpoints.
Secondary endpoints
Adverse medical outcome and length of hospital stay
A total of 65 patients (21.5%) experienced adverse medical
outcomes during the hospital stay: 30 patients died during
the hospital stay and, thus, the in-hospital mortality rate was
9.9%. Of the 30 patients who died, 28 suffered from severe
comorbidities, most frequently progressive malignant dis-
ease or liver cirrhosis, which subsequently lead to the
limitation of therapeutic interventions to a comfort level. A
total of 21 patients (7%) were transferred to the ICU. The
rates of overall adverse outcomes, mortality, ICU admis-
sion, recurrence and disease-specific complications were
similar in the survey and the ProHOSP control patients (see













All patients (n=302) (n=121) (n=116)
Duration of antibiotic treatment (days)
Median (quartiles) 6 (0–9) 7 (0–10) P=0.048 4 (0–8) P=0.08
Mean 5.99 7.1 5
Antibiotic prescription, % 71.5 74.4 P=0.63 63.8 P=0.16
Adverse medical outcome
Overall adverse outcome, % 21.5 24 P=0.61 16.4 P=0.28
Mortality, % 9.9 6.6 P=0.35 7.8 P=0.58
ICU admission, % 7 13.2 P=0.06 7.8 P=0.83
Recurrence, % 3.3 5 P=0.42 2.6 P=0.7
Disease-specific complication, % 3 3.3 P=1.0 0.9 P=0.3
Length of hospital stay, median (quartiles) 8 (5–13) 6 (2–11) P<0.001 7 (3–11) P=0.003
CAP (n=217, 71.9%) (n=66, 54.6%) (n=71, 61.2%)
Duration of antibiotic treatment (days)
Median (quartiles) 7 (4–10) 9 (7–11) P<0.001 7 (2–9) P=0.24
Mean 7.5 9.39 6.73
Antibiotic prescription, % 86.2 98.5 P=0.003 81.7 P=0.35
Overall adverse outcome, % 25.3 31.8 P=0.34 14.1 P=0.05
Mortality, % 11.5 9.1 P=0.66 7 P=0.37
Length of hospital stay, median (quartiles) 9 (6–13) 7 (3–12) P=0.04 7 (3–11) P=0.006
Exacerbation of COPD (n=29, 9.6%) (n=25, 20.7%) (n=20, 17.2%)
Duration of antibiotic treatment (days)
Median (quartiles) 0 (0–4) 4 (0–8) P=0.04 3 (0–7) P=0.08
Mean 1.97 3.84 3.7
Antibiotic prescription, % 31 64 P=0.02 60 P=0.08
Overall adverse outcome, % 17.2 16 P=1.0 25 P=0.72
Mortality, % 10.3 8 P=1.0 10 P=1.0
Length of hospital stay, median (quartiles) 7 (4–14) 5 (3–9) P=0.1 10 (4–12) P=0.98
Bronchitis (n=56, 18.5%) (n=26, 21.5%) (n=21, 18.1%)
Duration of antibiotic treatment (days)
Median (quartiles) 0 (0–4) 0 (0–0) P=0.24 0 (0–0) P=0.07
Mean 2.21 1.5 0.71
Antibiotic prescription, % 35.7 19.2 P=0.2 14.3 P=0.09
Overall adverse outcome, % 8.9 15.4 P=0.46 9.5 P=1.0
Mortality, % 3.6 0 P=1.0 4.8 P=1.0
Length of hospital stay, median (quartiles) 5 (1–10) 0 (0–5) P=0.004 0 (0–7) P=0.01
Eur J Clin Microbiol Infect Dis (2010) 29:269–277 273
Table 2). This was also true for subgroups of patients with
CAP, exacerbation of COPD and acute bronchitis. The
median length of hospital stay was significantly shorter in
both ProHOSP groups as compared to the survey popula-
tion. In the second half of the survey, the median length of
stay was significantly shorter than in the first (7 vs. 9 days,
P=0.016) and was similar to the ProHOSP groups.
Adherence to the PCT algorithm
In this survey, in 219 (73%) patients, antibiotics were
administered according to the prespecified PCT algorithm.
In the 83 (27%) patients who were overruled, the most
important overruling reasons were severe immunosuppres-
sion (22%), other infections in need of antibiotics (17%)
and anticipated complications (11%). Additionally, 37% of
patients were overruled because of the clinical judgement of
the treating physician without a prespecified reason
(Fig. 3). Overruled patients tended to be younger (median
age 65 [IQR 51–77] vs. 72 [IQR 57–82], P=0.07), tended
to have higher rates of immunosuppression (10.8% vs.
5.0%, P=0.07) and had higher rates of positive blood
cultures or legionella antigen tests (15.6% vs. 6.4%, P=
0.01). Overruling rate tended to decrease during the study
from 31% in the first half of the study to 24% in the second
study phase (P=0.15).
Comparison between overruled and not overruled survey
patients
The duration of antibiotic treatment in the non-overruled
group (4 days) was significantly shorter than in the
overruled group (11 days, P<0.001) (Table 3). Antibiotics
were prescribed in 60.7 and 100%, respectively (P<0.001).
The overall antibiotic exposure in the adherent group was
similar to the ProHOSP intervention group.
Discussion
In this observational survey, we found that in a real-life
setting and outside of controlled study conditions, a
previously validated PCT algorithm for antibiotic steward-
ship was effectively and safely implemented. In patients
with immunosuppression, antibiotic therapy was not adap-
ted according to the PCT algorithm, which complies with
the lack of evidence in these patients, because immuno-
suppression was an exclusion criterion in all of today’s
published PCT intervention studies and these patients may
be considered as high-risk patients.
In the randomised controlled, multicentre ProHOSP
study, we previously showed that PCT-guided antibiotic
stewardship markedly reduced antibiotic prescriptions in
patients with LRTI presenting to the emergency room
without increasing the risk of adverse outcomes [7].
Overall, the median duration of antibiotic treatment in the
current survey population with LRTI was only moderately
higher compared to the intervention group of the ProHOSP
study and significantly lower as compared to the control
group. For CAP patients, the survey population had similar
rates compared to the intervention group and significantly
lower rates as compared to the patients without PCT
guidance in the control group. These results indicate that,
also in a less stringent setting like in this survey, the use of
PCT as a surrogate biomarker can shorten the period of
antibiotic treatment.
Several of our observations merit further discussion. It is
not entirely clear why the length of hospital stay in this
current surveillance was longer than in the ProHOSP study
groups treated at the same site within a 2-year time frame.
The current survey included patients who were previously
excluded, particularly immunocompromised patients or
patients with severe comorbidities with expected imminent
death or co-infections. This was mirrored in a higher
proportion of patients with neoplastic disease in the survey
population. However, these differences in LOS remained
after the exclusion of these previously excluded subgroups
from the analysis (data not shown). Alternatively, partici-
pation in the ProHOSP study might have created a
Hawthorne effect influencing discharge behaviour. This
seems less likely, as LOS was not the primary endpoint of
the ProHOSP study and, furthermore, adverse outcomes
were not different between the survey and the ProHOSP
groups. Increasing use and confidence of physicians with
PCT over time could lead to inappropriately relying on PCT
as the sole or predominant marker influencing management
decisions other than antibiotic use, thereby, jeopardising
patients’ safety. Importantly, this concern was not supported
by the data of this survey as, e.g. ICU admission was
similar in the survey and the ProHOSP intervention group.
Interestingly, the length of hospital stay was significantlyFig. 3 Reasons for overruling
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shorter in the second period of the survey in parallel to the
improved adherence to the PCT algorithm.
An important focus of this study was to evaluate the
adherence to the PCT algorithm outside of stringent study
conditions. In 72.5% of cases, patients were treated
according to the algorithm. In 63% of overruled cases,
predefined overruling criteria (e.g. respiratory or haemody-
namic instability, need for ICU admission, severe immuno-
suppression or a concomitant infection in need of
antibiotics) were respected, while in 37% of overruled
patients, no obvious reason could be detected. Thus, we
achieved an overall algorithm compliance of 90% outside
Table 3 Comparison of antibiotic prescription and outcome in relation to algorithm adherence in patients included in the survey; comparison with
the ProHOSP control and PCT groups (values are presented in Table 2)
Non-overrulers Overrulers Non-overrulers
vs. overrulers
All patients (n=219) (n=83)
Duration of antibiotic treatment (days)
Median (quartiles) 4 (0–7) 10 (7–14) P<0.001
Mean 4.1 10.99
Antibiotic prescription, % 60.7 100 P<0.001
Adverse medical outcome
Overall adverse outcome, % 22.8 18.1 P=0.43
Mortality, % 12.8 2.4 P=0.005
ICU admission, % 5.9 9.6 P=0.31
Recurrence, % 4.1 1.2 P=0.21
Disease-specific complication, % 2.3 4.8 P=0.27
Length of hospital stay, median (quartiles) 8 (5–12) 9 (6–15) P=0.02
CAP (n=146) (n=71)
Duration of antibiotic treatment (days)
Median (quartiles) 6 (2–8) 10 (8–14) P<0.001
Mean 5.55 11.51
Antibiotic prescription, % 79.5 100 P<0.001
Overall adverse outcome, % 28.8 18.3 P=0.13
Mortality, % 16.4 1.4 P<0.001
ICU admission, % 6.8 11.3 P=0.27
Length of hospital stay, median (quartiles) 8 (6–13) 9 (6–15) P=0.27
Exacerbation of COPD (n=25) (n=4)
Duration of antibiotic treatment (days)
Median (quartiles) 0 (0–0) 6 (3–8) P=0.03
Mean 1.44 5.25
Antibiotic prescription, % 20 100 P=0.005
Overall adverse outcome, % 16 25 P=0.55
Mortality, % 8 25 P=0.37
ICU admission, % 8 0 P=0.56
Length of hospital stay, median (quartiles) 7 (4–12) 15 (6–24) P=0.2
Bronchitis (n=48) (n=8)
Duration of antibiotic treatment (days)
Median (quartiles) 0 (0–2) 8 (4–15) P<0.001
Mean 1.04 9.25
Antibiotic prescription, % 25 100 P<0.001
Overall adverse outcome, % 8.3 12.5 P=0.55
Mortality, % 4.2 0 P=1.0
ICU admission, % 2.1 0 P=0.68
Length of hospital stay, median (quartiles) 5 (0–10) 7 (4–14) P=0.29
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of study conditions, which is remarkable. Of note, the
adherence to the study algorithm was 91% and, thus,
similar to the ProHOSP trial [7]. The increasing compliance
with the algorithm over time likely resulted from a learning
effect and increasing confidence in PCT as a marker of the
treating physicians and becoming familiar with the PCT-
algorithm per se during the course of the study.
Within the survey cohort of patients, patients in the
overruled group had significantly more and longer antibi-
otic treatment courses than the adherent group. The overall
antibiotic exposure in the survey cohort was similar to the
ProHOSP intervention group. There was no difference in
the overall adverse medical outcome between overrulers
and non-overrulers, despite the markedly shorter period of
antibiotic therapy. This again approves the safety of the use
of the PCT algorithm and demonstrates the great potential
of PCT-guided therapy to reduce antibiotic exposure safely.
Of note, overruling occurs predominantly in patients
with low PCT levels below the respective cut-off ranges.
Mortality was significantly higher in the not overruled
group. This is explained by the fact that patients in this
group had higher PCT levels on admission to the hospital,
indicating a more severe bacterial infection and, thereby, a
poorer prognosis [4, 11, 12]. On the other hand, patients in
which overruling occurred had, by definition, lower PCT
values with subsequently lower risk of bacterial infection
and, rather, a higher chance of self-limiting viral aetiology
with low mortality [5, 11, 12].
PCT-guided antibiotic stewardship has great potential to
reduce the antibiotic mis- and overuse, which has been
repeatedly shown to be directly linked to bacterial resis-
tance in many settings [15–17]. As the effect of PCT on
antibiotic consumption other than in study conditions has
been unknown, this surveillance is encouraging and provides
important new insights and, thus, may further improve the
medical management of patients. Our current results mirror
the use of PCT-guided antibiotic therapy in clinical practice
and outside of trial conditions and demonstrate the feasibility
of excellent adherence to the algorithm in real life with the use
of only minor reminders, such as the instruction of new
employees and posted leaflets in work areas. Antibiotic
exposure strongly depended on this adherence. Using these
informal reinforcements, antibiotic exposure can be markedly
reduced, with subsequent reduction of antibiotic-associated
side effects, and possibly of antibiotic resistance, and health
care costs.
The strengths of this investigator-initiated observational
post-study survey are the investigation of a biomarker
strategy to reduce antibiotic over-prescription in real life
and the comparison of results with a well defined cohort of
LRTI patients from a previous study at the same institution.
Our study has limitations. First, a pre–post design may not
account for changes in routine practice during the study
time period and may, thus, overestimate the effect of
intervention. Second, the comparison of primary and
secondary endpoints between both cohorts is limited by
differences in the two patient populations due to different
inclusion criteria; while this survey included all patients
with LRTI, the ProHOSP study excluded some high-risk
patients, i.e. patients with immediate expected adverse
outcomes and immunosuppression. We expect a higher
complication rate and longer antibiotic courses in these
patients and this bias should, therefore, be conservative.
Third, as a former ProHOSP hospital, physicians in this
single-centre study were used to the treatment algorithm,
which potentially increases adherence. Thus, future studies
should investigate the effects of PCT guidance in different
hospitals and outside of Switzerland.
In conclusion, utilisation of the PCTalgorithm was feasible
and effective in clinical practice outside of study conditions.
Our observations indicate that the implementation of this
algorithm requires time and can be understood as a learning
process, where physicians become familiar with the PCT
algorithm step by step. Given the critical association between
adherence and effectiveness, ongoing reinforcement will
likely facilitate the success of this intervention and, thus,
ensure patient safety and the rational use of antibiotics,
minimising the imminent threat of antibiotic resistance with
individual and societal consequences. Multicentre surveil-
lance is the next logical step to assure the quality of more
widespread application of the algorithm.
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